Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer
- PMID: 11306387
- DOI: 10.1016/s0090-4295(00)01073-6
Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer
Abstract
Objectives: Serum acid phosphatase (ACP) was once used as the marker for advanced prostate cancer. However, with the development of assays for prostate-specific antigen (PSA), a more sensitive and specific tumor marker, the use of ACP has diminished. We investigated the prognostic value of preoperative serum ACP in predicting prognosis for men with localized prostate cancer following radical retropubic prostatectomy (RRP).
Methods: Of 2293 men treated from 1982 to 1998, 1681 men had a preoperative ACP measurement using an enzymatic assay. We analyzed the actuarial freedom from biochemical (PSA) progression following RRP according to ACP levels. We used multivariate logistic regression and proportional hazards models to determine the independent prognostic value of ACP level with respect of pathologic stage and biochemical recurrence.
Results: ACP was not an independent predictor of organ confinement or lymph node involvement in the multivariate logistic regression models using preoperative variables. However, in the proportional hazards model, ACP was an independent predictor of tumor recurrence following RRP, and there was a statistically significant improvement in biochemical recurrence-free survival for men with lower levels of ACP (P <0.001). Furthermore, the normalized hazard ratios of ACP and PSA for predicting biochemical recurrence were similar.
Conclusions: Stratification of men according to their preoperative ACP levels was predictive of patient outcome after RRP. Proportional hazards modeling using preoperative variables demonstrated that the serum ACP level is an independent predictor of tumor recurrence following RRP.
Similar articles
-
Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy.BJU Int. 2003 Dec;92(9):924-8. doi: 10.1111/j.1464-410x.2003.04506.x. BJU Int. 2003. PMID: 14632848
-
The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.J Urol. 1998 Mar;159(3):935-40. J Urol. 1998. PMID: 9474187
-
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.J Urol. 2003 Feb;169(2):517-23. doi: 10.1097/01.ju.0000045749.90353.c7. J Urol. 2003. PMID: 12544300
-
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.Urol Clin North Am. 2001 Aug;28(3):555-65. doi: 10.1016/s0094-0143(05)70163-4. Urol Clin North Am. 2001. PMID: 11590814 Review.
-
Treatment outcome after radical prostatectomy is not adversely affected by a pre-existing penile prosthesis.Urology. 1998 Dec;52(6):1030-3. doi: 10.1016/s0090-4295(98)00372-0. Urology. 1998. PMID: 9836550 Review.
Cited by
-
Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.J Proteomics. 2009 Aug 20;72(6):907-17. doi: 10.1016/j.jprot.2009.01.007. Epub 2009 Jan 20. J Proteomics. 2009. PMID: 19457353 Free PMC article. Review.
-
Markers for detection of prostate cancer.Cancers (Basel). 2010 Jun 4;2(2):1125-54. doi: 10.3390/cancers2021125. Cancers (Basel). 2010. PMID: 24281110 Free PMC article.
-
Moderate hypofractionated radiotherapy to the prostate bed with or without pelvic lymph nodes: a prospective trial.Rep Pract Oncol Radiother. 2024 Jun 6;29(2):187-196. doi: 10.5603/rpor.99677. eCollection 2024. Rep Pract Oncol Radiother. 2024. PMID: 39143977 Free PMC article.
-
Transmembrane prostatic acid phosphatase: a therapeutic target in advanced prostate cancer.Am J Clin Exp Urol. 2024 Oct 15;12(5):255-265. doi: 10.62347/DZIU5992. eCollection 2024. Am J Clin Exp Urol. 2024. PMID: 39584003 Free PMC article.
-
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.J Proteome Res. 2009 Feb;8(2):620-30. doi: 10.1021/pr8007545. J Proteome Res. 2009. PMID: 19128049 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous